CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and Prognosis

Panelists discuss how minimal residual disease (MRD) detection in patients with colorectal liver metastases (CLM) in the GALAXY study predicts both the benefit of adjuvant therapy and overall prognosis, potentially guiding more personalized treatment decisions.

EP: 1.Colorectal Cancer: Rising Prevalence and the Promise of ctDNA

EP: 2.ctDNA in CRC Management: Evolving Approaches for Personalized Care

EP: 3.MRD Detection in CRC: Guiding Postsurgical Treatment Decisions and Monitoring

EP: 4.MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control

EP: 5.DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer

EP: 6.ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies

EP: 7.GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC

EP: 8.GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC

EP: 9.Treatment Strategies in ctDNA-Positive CRC

EP: 10.GALAXY 24-Month Data from ESMO 2024: MRD Status and ctDNA Clearance Key in CRC

Now Viewing

EP: 11.CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and Prognosis

Recent Videos